JP2023510332A5 - - Google Patents

Info

Publication number
JP2023510332A5
JP2023510332A5 JP2022542294A JP2022542294A JP2023510332A5 JP 2023510332 A5 JP2023510332 A5 JP 2023510332A5 JP 2022542294 A JP2022542294 A JP 2022542294A JP 2022542294 A JP2022542294 A JP 2022542294A JP 2023510332 A5 JP2023510332 A5 JP 2023510332A5
Authority
JP
Japan
Prior art keywords
reducing
metabolism
agent
methyl
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510332A (ja
JP7728264B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012447 external-priority patent/WO2021142083A1/en
Publication of JP2023510332A publication Critical patent/JP2023510332A/ja
Publication of JP2023510332A5 publication Critical patent/JP2023510332A5/ja
Application granted granted Critical
Publication of JP7728264B2 publication Critical patent/JP7728264B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542294A 2020-01-10 2021-01-07 シトクロムp450の阻害剤を用いて3-((メチルスルホニル)アミノ)-2-(((4-フェニルシクロヘキシル)オキシ)メチル)ピペリジン-1-カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法 Active JP7728264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959514P 2020-01-10 2020-01-10
US62/959,514 2020-01-10
PCT/US2021/012447 WO2021142083A1 (en) 2020-01-10 2021-01-07 A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450

Publications (3)

Publication Number Publication Date
JP2023510332A JP2023510332A (ja) 2023-03-13
JP2023510332A5 true JP2023510332A5 (cg-RX-API-DMAC7.html) 2024-01-16
JP7728264B2 JP7728264B2 (ja) 2025-08-22

Family

ID=74418549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542294A Active JP7728264B2 (ja) 2020-01-10 2021-01-07 シトクロムp450の阻害剤を用いて3-((メチルスルホニル)アミノ)-2-(((4-フェニルシクロヘキシル)オキシ)メチル)ピペリジン-1-カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法

Country Status (10)

Country Link
US (1) US12594269B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087534A1 (cg-RX-API-DMAC7.html)
JP (1) JP7728264B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220127245A (cg-RX-API-DMAC7.html)
CN (1) CN115226390B (cg-RX-API-DMAC7.html)
AU (1) AU2021205892B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022013547A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167050A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022008392A (cg-RX-API-DMAC7.html)
WO (1) WO2021142083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
EP4600242A1 (en) 2022-10-07 2025-08-13 Kissei Pharmaceutical Co., Ltd. Cyclopentane compound
KR20250085056A (ko) 2023-12-05 2025-06-12 안희태 국궁 과녁에서 영역 구분 센서의 구성 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508334A (ja) * 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
AU2014244518A1 (en) 2013-03-14 2015-09-17 Pharmacyclics Llc Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
MA45848A (fr) 2016-08-04 2019-06-12 Gilead Sciences Inc Cobicistat destiné à être utilisé dans des traitements du cancer
JP2022547604A (ja) 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用
WO2021048822A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Similar Documents

Publication Publication Date Title
US12268723B2 (en) Peptidomimetics for the treatment of coronavirus and picorna virus infections
Das et al. A survey of the structures of US FDA approved combination drugs
JP2023541430A5 (cg-RX-API-DMAC7.html)
US10787502B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP4832045B2 (ja) メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物
TW200916103A (en) Therapeutic compositions and methods
Ghosh et al. Drug delivery to the oral cavity: molecules to market
US20210386858A1 (en) Mucoadhesive compositions and uses thereof
JP2022514089A5 (cg-RX-API-DMAC7.html)
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
NZ594618A (en) Transdermal pharmaceutical preparations
JP2006504795A5 (cg-RX-API-DMAC7.html)
JP2006508953A5 (cg-RX-API-DMAC7.html)
JP2019515909A5 (cg-RX-API-DMAC7.html)
JP2016528240A (ja) ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬
JP2013536837A5 (cg-RX-API-DMAC7.html)
JP2005508963A5 (cg-RX-API-DMAC7.html)
MX2007006343A (es) Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica.
TW201414508A (zh) 含5-氯-n-({(5s)-2-側氧-3-[4-(3-側氧-4-嗎啉基)苯基]-1,3-□唑啶-5-基}甲基)-2-噻吩甲醯胺之醫藥投遞型式
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
JP2010500284A5 (cg-RX-API-DMAC7.html)
JP2004538319A5 (cg-RX-API-DMAC7.html)
JP2023525981A5 (cg-RX-API-DMAC7.html)
JP2023512025A5 (cg-RX-API-DMAC7.html)